Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Combined Advanced Targeted Therapy for Inflammatory Bowel Disease: A Prospective, Multicenter, Real-World Study

NCT07660289 is registered in ClinicalTrials.gov with Xijing Hospital of Digestive Diseases as lead sponsor.

NCT NCT07660289
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07660289 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Combined Advanced Targeted Therapy for Inflammatory Bowel Disease: A Prospective, Multicenter, Real-World Study
Lead sponsor
Xijing Hospital of Digestive Diseases
Phase
Observational
Overall status
Completed
Start date
April 20, 2023
Completion date
June 10, 2026
Enrollment
117 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

combination therapy, combined advanced targeted therapy, ibd (inflammatory bowel disease)